List of Excipients in Branded Drug DIHYDROERGOTAMINE MESYLATE NASAL

Generic Drugs Containing DIHYDROERGOTAMINE MESYLATE NASAL

Company	Ingredient	NDC	Excipient
Cipla USA Inc	dihydroergotamine mesylate nasal	69097-503	ANHYDROUS DEXTROSE
Cipla USA Inc	dihydroergotamine mesylate nasal	69097-503	CAFFEINE
Cipla USA Inc	dihydroergotamine mesylate nasal	69097-503	CARBON DIOXIDE
Cipla USA Inc	dihydroergotamine mesylate nasal	69097-503	WATER
Cipla USA Inc	dihydroergotamine mesylate nasal	69097-740	ANHYDROUS DEXTROSE
Cipla USA Inc	dihydroergotamine mesylate nasal	69097-740	CAFFEINE

What are the Most Frequently-Used Excipients in DIHYDROERGOTAMINE MESYLATE NASAL?

# Of NDCs	Excipient
3	ANHYDROUS DEXTROSE
3	CAFFEINE
3	CARBON DIOXIDE
3	WATER

Dihydroergotamine Mesylate Nasal Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Dihydroergotamine mesylate nasal products compete on rapid migraine relief, systemic exposure, device performance, and tolerability rather than on active-ingredient novelty. The commercial opportunity is strongest in differentiated nasal delivery, preservative-free multidose systems, improved usability, and lower-cost generic or specialty formulations. Trudhesa, an FDA-approved dihydroergotamine mesylate nasal spray using Impel NeuroPharma's Precision Olfactory Delivery technology, established a premium reference product, while Migranal provides the earlier nasal benchmark.[1][2]

What is dihydroergotamine mesylate nasal?

Dihydroergotamine mesylate is an ergot alkaloid used for the acute treatment of migraine with or without aura. Nasal delivery avoids gastrointestinal absorption and provides an alternative to injectable administration. The product class is distinct from oral triptans, gepants, and monoclonal antibodies because it combines an established vasoconstrictive mechanism with nonoral administration.

Product	Sponsor or manufacturer	FDA status	Dose	Delivery format
Migranal	Originally Valeant, later marketed by multiple companies	NDA-approved	0.5 mg per spray; usual dose 1 mg	Conventional nasal spray
Trudhesa	Impel NeuroPharma	FDA approved in 2021	0.725 mg per spray; two sprays deliver 1.45 mg	Precision Olfactory Delivery nasal system
Generic DHE nasal	Abbreviated pathway candidate	Market opportunity depends on reference-product and device strategy	Comparable to reference product	Conventional or proprietary nasal device

Trudhesa's approved labeling describes a single-use unit-dose container and a reusable device assembly. The product is administered as one spray in each nostril, with a second dose permitted under specified conditions. Migranal uses a different nasal delivery format and dose presentation.[1][2]

What excipients are used in dihydroergotamine mesylate nasal products?

The core excipient system is an aqueous buffered vehicle containing caffeine, sugars, phosphate salts, sodium chloride, and water. The excipient package supports solubility, tonicity, pH control, chemical stability, and nasal tolerability.

Public FDA labeling identifies the following inactive ingredients for Trudhesa:

Excipient	Primary formulation function	Commercial relevance
Caffeine	Solubilization and possible absorption-supporting function	May contribute to drug loading and local tolerability considerations
Dextrose	Tonicity adjustment and vehicle stabilization	Supports isotonicity without relying solely on sodium chloride
Potassium phosphate monobasic	Buffer component	Controls pH and supports chemical stability
Sodium phosphate dibasic	Buffer component	Establishes phosphate buffer capacity
Sodium chloride	Tonicity adjustment	Helps approximate nasal-fluid osmolality
Water for injection or purified aqueous vehicle	Solvent	Determines microbial, extractables, and stability requirements

The precise commercial composition, concentration ranges, manufacturing controls, and device-contact materials are not fully disclosed in the public label. Those details normally reside in the chemistry, manufacturing, and controls section of the NDA.

Why caffeine matters in the formulation

Caffeine is unusual as a functional excipient because it can act as both a formulation aid and a pharmacologically active migraine-related ingredient. It may improve apparent solubility or influence mucosal permeation, but its inclusion creates additional requirements for dose uniformity, impurity control, local tolerability, and clinical comparability.

A generic developer cannot assume that replacing caffeine with a conventional solubilizer will preserve bioequivalence. The substitution could alter:

• Dihydroergotamine solubility.
• Nasal deposition.
• Absorption rate.
• Local irritation.
• Drug-device compatibility.
• Pharmacokinetic exposure.
• Comparative clinical effect.

Why phosphate buffering matters

Dihydroergotamine mesylate is sensitive to formulation conditions that affect solubility and degradation. A phosphate buffer allows control of pH while maintaining an aqueous presentation. The commercial design objective is a narrow operating window that balances:

1. Chemical stability of dihydroergotamine.
2. Solubility at the target concentration.
3. Nasal comfort.
4. Compatibility with the container and pump.
5. Sterility or microbial-control requirements.

A higher buffer concentration may improve pH control but increase the risk of local irritation or altered mucosal tolerability. A lower concentration may reduce buffering capacity during storage or administration.

How should an excipient strategy be designed for DHE nasal products?

The preferred strategy is a low-complexity, aqueous, buffered formulation with excipients that have established nasal or parenteral use. The highest-value development work is unlikely to involve a large excipient count. It is more likely to involve concentration optimization, preservative selection, device compatibility, and deposition control.

Formulation priorities

Development objective	Preferred strategy	Main risk
Maintain DHE solubility	Use pH-controlled aqueous system with validated buffer capacity	Precipitation during storage or after temperature excursions
Improve nasal tolerability	Target near-isotonic, low-irritancy formulation	Reduced drug loading or weaker stability
Control microbial risk	Use unit-dose packaging or a qualified preservative system	Higher packaging cost or preservative irritation
Improve absorption	Optimize droplet size, viscosity, and device plume	Changed deposition can create bioequivalence problems
Protect potency	Use low-oxygen, light-controlled packaging and validated process controls	Oxidation, adsorption, or extractables
Support commercial scale	Select common compendial excipients and standard manufacturing processes	Lower differentiation from generics

Preservative-free versus preserved formulations

A preservative-free product has a commercial advantage in chronic or repeated-use nasal markets because benzalkonium chloride and other preservatives can raise concerns about local irritation and epithelial effects. Unit-dose packaging can reduce microbial risk without adding a preservative.

The tradeoff is cost. A unit-dose or single-use system requires more packaging components, more assembly controls, and potentially a more complex device. A multidose preserved system can reduce packaging cost but introduces preservative qualification, extractables and leachables assessment, and local tolerability work.

For DHE, the preservative-free route is commercially attractive if the device can maintain dose uniformity and microbial control through the labeled in-use period.

What formulations are protected by DHE nasal patents?

The protectable value in DHE nasal products typically lies in the combination of formulation, delivery device, dosing method, and nasal deposition rather than in the public-domain active ingredient.

Likely patent-protected subject matter

Patent portfolios for advanced DHE nasal products can include:

• Specific DHE mesylate concentration ranges.
• Buffered aqueous compositions.
• Caffeine-containing formulations.
• pH and osmolality ranges.
• Droplet-size distributions.
• Device geometries that direct spray toward the upper nasal cavity.
• Delivery methods targeting the olfactory region.
• Multi-dose or unit-dose container systems.
• Priming, actuation, and dose-counting mechanisms.
• Methods for treating migraine with defined intranasal dosing.
• Stability improvements and packaging configurations.

The strongest claims generally require multiple elements. A claim directed only to DHE in an aqueous nasal formulation is more vulnerable to prior-art and obviousness challenges than a claim combining a defined excipient system with a specialized device and deposition profile.

How strong is the patent estate for Trudhesa and Migranal?

Trudhesa has a stronger product-differentiation position than conventional DHE nasal spray because the delivery system is central to the product's clinical and commercial identity. The relevant protection is likely to be distributed across formulation, device, and method-of-use claims.

Migranal's formulation and active ingredient have substantially older development histories. Its remaining barriers are more likely to involve regulatory equivalence, manufacturing know-how, device configuration, and market access than broad composition-of-matter protection.

Patent-estate factor	Trudhesa	Migranal
Active ingredient protection	Expired or commercially exhausted	Expired or commercially exhausted
Formulation protection	Potentially material	Older and more vulnerable
Device protection	Central to product differentiation	Less differentiated
Method-of-use protection	Possible	Possible but generally narrower
Generic substitution risk	Moderate, depending on device and pathway	Higher
Manufacturing barrier	Device assembly and dose delivery	Conventional nasal manufacturing
Commercial moat	Delivery technology and usability	Brand history and market familiarity

The principal legal risk for Trudhesa is a design-around that reproduces clinically relevant exposure with a different device or excipient system. The principal regulatory risk is that FDA requires more than simple pharmaceutical equivalence because nasal deposition and device performance can affect pharmacokinetics.

What is the FDA regulatory status of dihydroergotamine mesylate nasal spray?

The FDA approved Trudhesa in September 2021 for the acute treatment of migraine with or without aura in adults.[1] Migranal was approved earlier as a conventional nasal spray.[2]

A future generic applicant could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. The regulatory burden may include:

• Same active ingredient and strength.
• Comparable dosage form and route.
• Equivalent device performance.
• Dose-delivery consistency.
• Spray content uniformity.
• Priming and repriming performance.
• Droplet-size distribution.
• Plume geometry.
• Container-closure integrity.
• Extractables and leachables.
• Comparative pharmacokinetics.
• Local tolerability, if required by FDA.

A complex device can increase the probability that a competitor needs a device-specific development program rather than a straightforward copy.

When does dihydroergotamine nasal lose exclusivity?

Dihydroergotamine nasal products do not depend on a current new-molecular-entity exclusivity period. The active ingredient has been marketed for decades. Commercial exclusivity therefore depends on the remaining listed patents, regulatory exclusivity, device-related protection, and the practical time required to develop a substitutable nasal product.

For Trudhesa, the commercial loss-of-exclusivity analysis should separate four dates:

1. FDA approval and any applicable regulatory exclusivity.
2. Expiration of Orange Book-listed formulation patents.
3. Expiration of device patents.
4. Earliest legally effective generic launch date after Paragraph IV litigation or settlement.

A patent expiration date alone does not establish the actual launch date. A generic may launch earlier under a license, after a court decision, or at risk. Conversely, a patent that expires later may have limited commercial value if competitors can design around it.

Which companies are challenging or competing with DHE nasal products?

The competitive landscape includes three groups.

Generic pharmaceutical companies

Potential entrants include companies with experience in nasal sprays, sterile liquids, migraine products, or complex generics. The most credible candidates are those with:

• Existing FDA-approved nasal manufacturing.
• Spray-device engineering capability.
• Experience with ANDA litigation.
• Access to DHE analytical standards and validated assays.
• Commercial relationships with specialty pharmacies and neurologists.

Branded migraine companies

DHE nasal competes with:

• Sumatriptan and other triptan nasal sprays.
• Oral and orally disintegrating triptans.
• Ubrogepant, rimegepant, and zavegepant.
• Dihydroergotamine injection.
• Nonpharmaceutical neuromodulation devices.

Gepants have a major commercial advantage for patients with triptan contraindications or intolerance because they do not carry the same vasoconstrictive profile. DHE nasal retains a role where rapid nonoral treatment and established migraine efficacy are priorities.

Device and formulation licensors

The most valuable licensing targets are companies with nasal deposition platforms, preservative-free multidose systems, spray-drying or particle-engineering capabilities, and validated nasal bioequivalence programs. A platform license could support additional products using the same device architecture, including rescue therapies, peptides, and other poorly absorbed molecules.

What commercial opportunities exist for DHE nasal excipients?

1. Excipient-enabled generic differentiation

A generic company can differentiate through:

• Preservative-free packaging.
• Improved shelf life.
• Reduced nasal irritation.
• Lower-cost device assembly.
• Improved priming and dose counting.
• More compact packaging.
• Better temperature excursion performance.

These changes may create commercial value even when the active ingredient is identical.

2. Reformulation for improved tolerability

DHE's vasoconstrictive mechanism and nasal administration can limit use in some patients. A lower-irritancy formulation may improve adherence and repeat use. Opportunities include optimizing buffer strength, tonicity, surfactant-free solubilization, and container-contact materials.

A reformulation that changes excipients can require clinical or bioequivalence evidence if it changes exposure or delivery behavior.

3. Multidose systems

A multidose system can lower cost per treated migraine episode and improve convenience. It must demonstrate accurate delivery over the labeled number of doses, resistance to contamination, and stable performance after repeated actuation.

The main development barriers are microbial control, dose uniformity, pump recovery, and container-closure performance.

4. Combination products

A DHE nasal product could be positioned with antiemetic or migraine-supportive therapy, but combining active ingredients in one nasal system would create substantial formulation and regulatory complexity. The more practical opportunity is co-packaging with an oral antiemetic, digital dosing support, or an acute-migraine treatment kit.

5. International expansion

Regulatory pathways outside the United States may offer opportunities where DHE nasal products have limited competition. Priority markets are those with:

• Established migraine diagnosis and treatment infrastructure.
• High injectable-avoidance demand.
• Specialist prescribing.
• Reimbursement for branded or complex nasal products.
• Local manufacturing or licensing incentives.

Geographic freedom-to-operate must be assessed separately because device and formulation patents can have different national filing and expiration profiles.

What generic launch risks exist for DHE nasal spray?

The main risks are technical and regulatory rather than active-ingredient discovery risks.

Risk	Impact on launch
Failure to match spray plume and droplet distribution	May prevent bioequivalence or device equivalence
Different excipient solubilization system	Can alter DHE exposure
Device patent claims	May require a noninfringing delivery platform
Weak stability profile	Increases development and inventory costs
Nasal irritation	Can impair clinical acceptance
Complex packaging	Raises unit cost
Small commercial market	May reduce return on development investment
Paragraph IV litigation	Can delay approval or require at-risk launch

A conventional nasal copy may be technically simpler than a precision-deposition product but could have difficulty demonstrating comparable exposure if the reference product depends on upper-nasal deposition.

What licensing deals could create value?

The most attractive transaction structures are:

• Device-platform licensing with milestone payments.
• Regional commercialization rights.
• Co-development of a preservative-free DHE product.
• Acquisition of a nasal spray manufacturing site.
• Licensing of a generic-ready formulation and analytical package.
• Portfolio deals covering DHE plus additional migraine or rescue products.

A licensee should value the asset based on remaining patent term, reference-product sales, development cost, expected price erosion, device complexity, and the probability of FDA acceptance of the proposed equivalence approach.

Key Takeaways

• Dihydroergotamine mesylate nasal is an established active ingredient; value is concentrated in formulation, device, deposition, and regulatory execution.
• Trudhesa's excipient strategy uses an aqueous phosphate-buffered system with caffeine, dextrose, sodium chloride, and water.
• Caffeine, buffer concentration, tonicity, and device performance are likely to be critical formulation variables.
• Preservative-free unit-dose delivery is a credible commercial differentiation strategy, although it increases packaging cost.
• Trudhesa has a stronger commercial moat than conventional DHE nasal spray because its delivery technology is central to product performance.
• Generic entry risk depends on device equivalence, patent scope, and the ability to reproduce exposure without copying protected delivery features.
• The best licensing opportunities involve nasal-device platforms, preservative-free systems, complex-generic development, and international commercialization.

FAQs

Can caffeine be removed from a DHE nasal formulation?

Yes, but removal may change solubility, absorption, local tolerability, and bioequivalence. A caffeine-free formulation would require a new optimization and comparative regulatory strategy.

Is dihydroergotamine mesylate nasal a biologic?

No. Dihydroergotamine mesylate is a small-molecule ergot alkaloid. Biosimilar pathways do not apply; competition would generally proceed through generic, hybrid, or locally applicable pharmaceutical pathways.

Does a new DHE nasal excipient system require clinical trials?

Not necessarily. The requirement depends on the extent of formulation and device change, its effect on exposure, the applicable FDA pathway, and the evidence needed to establish equivalence.

Which excipient has the greatest commercial leverage?

The device-compatible solubilization and stabilization system has the greatest leverage. In the public formulation, caffeine and phosphate buffering are especially important because changes can affect both product performance and bioequivalence.

Can a company launch a DHE nasal generic before all device patents expire?

Potentially. An applicant may design around unexpired claims, obtain a license, prevail in Paragraph IV litigation, or launch under a settlement arrangement. The outcome depends on the specific patent claims and applicable regulatory exclusivity.

References

1. U.S. Food and Drug Administration. (2021). Trudhesa (dihydroergotamine mesylate) nasal spray prescribing information.
2. U.S. Food and Drug Administration. (1997). Migranal (dihydroergotamine mesylate) nasal spray prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. U.S. Food and Drug Administration. (2016). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry.
5. U.S. Food and Drug Administration. (2022). Nasally administered locally acting products: CMC and bioequivalence considerations.